Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methimazole + pentoxifylline
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination of two medications. Methimazole is a thionamide antithyroid agent that inhibits thyroid hormone synthesis by blocking the action of thyroid peroxidase, leading to reduced hyperthyroidism. Pentoxifylline is a methylxanthine derivative that improves blood flow and circulation by making blood thinner and blood vessels wider. While methimazole is primarily used for hyperthyroidism, pentoxifylline has shown beneficial effects in thyroid-associated ophthalmopathy (TAO) by reducing inflammatory symptoms and associated laboratory parameters.
02
Targets
ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)PDE (Phosphodiesterase family)TPO (Thyroid peroxidase)NT5E (Cluster of Differentiation 73)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on methimazole + pentoxifylline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methimazole + pentoxifylline.